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Abstract 
Background: Inflammation and edema Symptoms are physiological 
responses to triggers induced by different mediators such as cytokines. 
Rheumatoid arthritis is the most common form of arthritis which is characterized 
by chronic inflammation of the synovial membrane, severe and debilitating pain, 
and progressive cartilage injury. It is clear that cytokines are involved in different 
stages of inflammation by inducing pro-inflammatory effects; TNF-α is a cytokine 
involved in the pathogenesis of rheumatoid arthritis. In this study, we attempted 
to investigate the role of the prescription of calcium to reduce inflammatory edema 
and serum TNF-α levels during different stages of arthritic inflammation induced 
by Complete Freund Adjuvant (CFA) injection in males Wistar rats. 
Materials and Methods: In this Applicable-Fundamental study, we used male 
Wistar rats and adjuvant arthritis was created by once the subcutaneous injection 
of CFA in the right hind paw of animals on day zero in experimental groups. 
Various doses of calcium were prepared and injected within 21 days of the study. 
Hyperalgesia and paw volume changes were assessed by radiant heat and 
plethysmometer over several days, respectively. The serum levels of TNF-α were 
studied by ELISA standard kit of rats during various phases and were measured 
according to the kit. 
Results: The results indicated dose-related effects of long-term calcium 
administration on edema, hyperalgesia, and serum TNF-α level reduction. Daily 
treatment with an effective dose of calcium (5 mg/kg) in the AA+ Ca group 
significantly decreased paw edema, hyperalgesia, and serum TNF-α level in 
comparison to AA and AA+ Vehicle groups on days 7, 14, and 21 of the study. 
Conclusion: Findings of this study showed; long-term administration of calcium 
in the proper dosage can act as an anti-inflammatory agent and pain modulator 
during adjuvant-induced arthritis. A part of those effects may be conducted by 
decreasing serum TNF-α levels. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory 
disease characterized by swelling, tenderness, and 
destruction of synovial joints and leading to severe 
disability (1). Inflammation is the primary and 
essentially a salutary response that normally resolves 
with the restoration of normal tissue structure and 
function, however when inflammation persists 
(chronic inflammation) it can cause tissue damage and 
1. Neurophysiology Research Center, 
Physiology Department, Shahid 
Beheshti University of Medical 
Sciences, Tehran, Iran 
2. International Branch of Shahid 
Beheshti University of Medical 


























Corresponding Author:  
Jalal Zaringhalam, MD; Neuro-
physiology Research Center, Shahid 
Beheshti University of Medical 
Sciences, Tehran, Iran. Email: 
jzaringhalam@yahoo.com 
Received: November 20, 2015 
Accepted: November 12, 2015 
Anti-Hyperalgesic Effects of Long Term Calcium                                                                                Khashaee et al. 
Vol 1, No 1, Winter 2016 
13 
loss of function. It results in rapid elevation of the 
secretion of inflammatory mediators, chemokine, and 
cytokines, such as interleukins 1 and 6 (IL-1 and IL-6) 
and tumor necrosis factors α (TNFα). Pain and 
disability are the principal clinical features of 
inflammation. This situation is associated with the 
sensitization of specialized sensory neurons that 
comprise the nociceptive (pain) pathway (2). TNFα is 
a key cytokine involved in the pathogenesis of RA, 
resulting in a chronic inflammatory state in which the 
synovial membrane is the primary site of the attack. 
Therapies directed against tumor necrosis factor (TNF) 
are effective for the treatment of rheumatoid arthritis 
and reduce pain scores in this condition (3). 
Therapeutic approaches used in the treatment of RA 
symptoms are traditional non-selective no steroidal 
anti-inflammatory drugs (NSAIDs), disease-
modifying anti-rheumatic drugs (DMARDs), 
glucocorticoids, and biologics, which have partial 
clinical benefit and are associated with significant 
toxicity (4). Due to the side-effects and high cost of 
these immunomodulatory agents, patients with RA 
often seek alternative methods for symptomatic relief 
and are among the highest users of such methods. 
Nutritional supplements such as vitamins with fewer 
side effects have been proven to significantly reducing 
inflammation. The use of vitamin compounds and 
supplements as analgesics for pain treatment which are 
associated with deficiency of these components are 
common. Recently they have been considered more 
than before because of their effectiveness and have no 
side effects (unlike chemical drugs) and also be easy to 
access (5). 
Calcium ion, as a usual supplement, plays an 
important role in the release of inflammatory mediators 
or activating them and contributes to their effects. Also 
reported that calcium activates phospholipase-A2 and 
ultimately increases the metabolism of arachidonic 
acid products (6), activates protein kinase-C, 
production of NO (7), and Releasing interleukins (8). 
It is known that releasing of these mediators, triggers 
exocytosis movement of inflammatory cells, 
neutrophils, and macrophage chemicals secretes (9), 
increase level of LTB4, lymphocyte (10), and adhesion 
of the white blood cell to vascular endothelial cells and 
their migration to the site of inflammation (11). 
Therefore, the present study was carried out to evaluate 
the anti-hyperalgesic and anti-inflammatory effects of 
calcium long-term treatment in adjuvant-induced 
arthritis with emphasis on pro-inflammatory cytokine, 
serum TNFα level. 
 
Methods 
Animals: The study protocol was approved by the 
local ethics committee for the use of animals in 
research, and we followed the guidelines of ethical 
standards for the investigation of experimental pain in 
animals (2). Adult male Wistar rats (180–220 g) were 
used for all animal experiments. The photoperiods 
were adjusted to 12 hours (h) light and 12 h darkness 
daily, and the environmental temperature was 
constantly maintained at 25±2°C and humidity 55%. 
The rats were kept in cages housing 4-6 animals and 
were given ad libitum access to food and water. The 
study was carried out after a period of 21 days of 
acclimatization.  
Four groups of male Wistar rats (n=6) were used 
in this study. Animals fasted overnight with free access 
to water before the experiment. Thereafter group I 
(control group) received 0.1 ml Oil emulsion (as CFA 
solvent), group II (AA group) received 0.1ml CFA, and 
groups III (AA+ vehicle group) received double distill 
water (calcium solvent) via intraperitoneal (IP) 
injection with the same volume injected in a therapy 
group for 21 days after CFA injection, groups IV (AA+ 
Ca group). This group also had three sub-groups, 
which after CFA injection they have received calcium 
in doses of 2/5, 5, and 10 mg/kg (IP). The volume of 
all IP treatments was 1ml/rat on each day. 
 
Induction of adjuvant arthritis (AA): AA was 
induced at day 0 as expressed in our previous studies. 
Briefly, a single subcutaneous injection (100l) of 
heat-killed Mycobacterium tuberculosis suspended in 
sterile mineral oil (10 mg/ml), CFA (Sigma, St Louis, 
MO, USA), into the left hind paw was performed. The 
left hind paws of control rats were injected with sterile 
mineral oil only (100l). The first day after CFA 
injection unilateral inflammation was established in 
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injected hind paw then the first week was considered 
as an inflammatory phase. The third week after the 
intervention was the arthritic phase (12).  
 
Paw volume assessment: Paw volume variations were 
assessed by plethysmometer (Ugo Basile; model7141; 
Comerio VA, Italy) during different stages of study 
(days 0, 7, 14, and 21) as was mentioned previously in 
our lab (12, 13). In brief, rats’ hind paw was submerged 
to the tibiotarsal joint into an electrolyte-filled Perspex 
cell of the plethysmometer after taken out of their 
cages. The volume of liquid displacement, which is 
equal to the paw volume, was indicated on a digital 
display. Volume measurement was done twice for each 
paw, and the average was calculated. The amount of 
paw edema was calculated by measuring the difference 
in volume between baseline and various times. 
It should be noted that according to previous 
studies, the first week of illness is considered the 
inflammatory phase (acute arthritis), and the second 
and third weeks are known as chronic arthritis (14). 
 
Behavioral test: For behavioral test especially thermal 
hyperalgesia (Paw Withdrawal Latency (PWL)) from 
noxious heat) was assessed by using the plantar test 
(Ugo Basile, Verse, Italy) in different experimental and 
control rats on days 0, 3, 7, 14, and 21 as previously 
described (12). Briefly, rats were habituated to the 
apparatus that consisted of three individual Perspex 
boxes on a glass table. A mobile radiant heat source 
was located under the table and focused onto the 
desired paw. PWLs were recorded three times for both 
hind paws of each animal, the mean of which 
represented baseline for left (CFA-injected paw) and 
right hind paws. Then, the mean value for the affected 
paw (CFA-injected paw) was subtracted from that for 
the other paw and the result was considered as the 
hyperalgesia sign in the injured paw. To prevent tissue 
damage of the plantar zone, a 20-s cut-off was 
observed. 
 
Measuring blood levels of TNF-α:  The serum TNF-
α levels of rats were assayed by a rat standard ELISA 
kits (Koma Biotech, Seoul, Korea) on day 0 (before 
CFA injection) and at different phases of the study 
(days 7, 14, and 21) according to the manufacturer’s 
protocol. Rats were anesthetized with isoflurane and 
their blood samples were taken from the vessel retro-
orbital corners of their eyes with a heparin capillary 
tube. These samples were centrifuged and the serum 
was stored at -80°C. TNF-α was measured by using a 
commercial enzyme-linked immunosorbent assay 
(ELISA) kit (12, 13). Kit's interaction with rat serum 
and TNF-α was 100% (15). 
 
Statistical methods: Data are presented as 
mean±standard error of the mean (SEM). Statistical 
analysis of thermal hyperalgesia, paw edema, and 
serum TNF-α level was analyzed by one-way analysis 
of variance (SPSS software; version 18). Repeated 
measurement and post hoc analysis were performed 
with Tukey’s multiple comparison tests where 
appropriate. For comparing variations between groups 
on the same days an unpaired t-test was done. 
Statistical significance was accepted at p<0.05. 
 
Results 
Paw volume changes during different stages of 
study: CFA injection in the right hind paw of rats at 
day zero induced inflammation and edema in the same 
paw. This increase continued until day 21 after the 
injection. Paw volume on days 7, 14, and 21 after CFA 
injection significantly increased compared to baseline 
on day zero (p<0.001). Also, our results indicated that 
the volume of inflamed paw at days 14 and 21 were 
significantly increased compared to day 7 (p<0.001). 
Calcium administration significantly reduced 
the increased volume of rats’ paws within 21 days after 
CFA injection. The results showed; calcium long-term 
treatment at a dose of 5 mg/ kg significantly reduced 
the volume of paw at days 7, 14, and 21 after CFA 
injection (p<0.01 for day 7 and p<0.001 for days 14 
and 21). Our study also points out that, continuous 
daily administration of 5 mg /kg dose of calcium 
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significantly reduced paw volume on days 14 and 21 in 
comparison to day 7 in the AA+Ca group (p<0.05). 
There was no statistically significant difference 
between 5 and 10 mg/kg doses of calcium in edema 
reduction during our study in the AA+Ca group, 
therefore 5 mg /kg was considered as the effective 
dose. Also, results showed that 2.5 mg/kg did not affect 
paw volume variation during 21 days injection in our 
experimental groups. It should be noted that injection 
of calcium solvent in AA+Vehicle group demonstrated 
no difference in paw volume variations when 
compared with AA group on different days of the study 
(Figure 1A and B). 
 
 
Thermal hyperalgesia variations during different 
stages of study: Arthritic rats by injection of CFA 
showed thermal hyperalgesia changes in the injected 
paw during different stages of inflammation. 
Hyperalgesia was significantly increased on day 7 after 
CFA injection compared to day zero and the control 
group (p<0.001 for both).  
 
Fig. 1.  Effects of administration of different doses of calcium on reducing paw volume during 21 days 
inflammation induced by CFA. (A): 5 mg/ kg doses of calcium significantly reduced paw edema in AA+Ca 
compared to AA groups. (B): Paw volume showed significant decrease on 14 and 21 compared to day 7 in AA+ 
Ca with 5 mg/kg doses. 
 
Fig. 2.  Effects of treatment by different doses of calcium long term administration on thermal hyperalgesia 
variations in AA rats during 21 days of study. (A): 5 mg/kg Calcium long term treatment significantly reduced 
hyperalgesia in AA+Ca compared to AA groups. (B): Hyperalgesia indicated significant decrease on 14 and 
21 compared to Day 7 in AA+Ca group when received effective dose of calcium (5 mg/kg). 
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Results showed that when paw inflammation 
continued hyperalgesia significantly decreased at days 
14 and 21 compared to day 7 of the study in the AA 
group (p<0.001 for both). In addition, hyperalgesia 
showed a significant decrease on day 21 compared to 
day 14 in AA rats (p<0.001). 
Daily calcium administration reduces 
hyperalgesia in the AA+Ca group. It was showed a 
significant reduction in hyperalgesia after taking 5 
mg/kg calcium supplementation in AA+Ca compared 
with AA groups on days 7, 14 of the study (p<0.001 
for both days). There was no statistically significant 
difference between 5 and 10 mg/kg calcium on 
reducing hyperalgesia in AA+Ca rats, therefore 5 
mg/kg was considered as the effective dose. Also, 
results showed that 2.5 mg/kg did not affect 
hyperalgesia variations during 21 days treatment in 
AA+Ca rats. It should be noted that injection of 
calcium solvent in the AA + vehicle group indicated no 
significant effect on hyperalgesia variations when 
compared with the AA group during different stages of 
study (Figure 2A and B). 
 
Serum TNF-α levels changes during different stages 
of study: CFA injection induced a significant increase 
in serum levels of TNF-α and this continued up to day 
21 after the injection. Plantar CFA injection 
significantly increased serum levels of TNF-α level on 
days 7, 14, and 21 after injection compared with day 
zero (p<0.001). TNF-α levels on days 14 and 21 of the 
study were significantly higher than day zero but 
showed a significant decrease over day 7 (for both 
p<0.001).  
Daily calcium administration reduces serum 
levels of TNF-α. The results showed a significant 
reduction in serum levels of TNF-α after taking 5 
mg/kg calcium supplementation in AA+Ca compared 
with the AA group on days 7, 14, and 21 of the study 
(p<0.001 for all three days). 
Moreover, continues treatment by 5 mg/kg 
calcium in the AA+Ca group significantly reduced   
TNF-α levels on days 14 and 21 when compared with 
day 7 (p<0.01). There was no statistically significant 
difference between 5 and 10 mg/kg doses of calcium in 
TNF-α level reduction then, 5mg/kg was considered as 
the effective dose. Also, our results demonstrated that 
2.5 mg/kg dose of calcium had no significant effect on 
serum TNF-α level change during 21 days of 
administration in the AA+Ca group. Furthermore, 
administration of calcium solvent in the AA + vehicle 
group had no significant effect on serum TNF-α level 
fluctuations when compared to the AA group during 
different days of study (Figure 3A and B). 
 
Discussion 
This study along with other studies showed that the 
 
Fig. 3.  Effects of administration of different doses of calcium on serum TNF-α level during different stages of 
study. (A): Administration of 5 mg/ kg Calcium significantly reduced serum TNF-α levels in AA+Ca rats. (B): 
Serum TNF-α level indicated significant reduction on 14 and 21 compared to day 7 in AA+Ca group when 
received effective dose of calcium. 
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inflammation model induced by CFA is a two-phase 
model. In the first phase, hyperalgesia and paw edema 
were increased by the presence and significant increase 
in the serum level of the pro-inflammatory cytokine, 
TNF-α. Although the molecular mechanisms of TNF-
α are not exactly clear, the use of antagonists is now a 
widely used method in clinical treatment and may have 
a role in alleviating the symptoms of the inflammation 
(12, 19). It is clear that the first phase inflammatory 
response during CFA- induced local response is along 
with the release of mediators such as cytokines, 
particularly TNF-α and IL-1ß (12, 16, 17). Our results 
also indicated that hyperalgesia significantly decreased 
in the second phase of CFA inflammation (next two 
weeks) which was along with a significant reduction of 
TNF-α level. Previous studies indicated that activating 
of pain modulatory systems such as anti-inflammatory 
cytokines secretion increase and opioid system 
activation may cause pain modulation during 
inflammation (2, 3). 
Moreover; long-term administration of calcium 
in CFA-inflamed rats significantly caused the dose-
dependent reduction (5 mg/kg) in hyperalgesia and 
paw edema throughout the observation period. Our 
findings also revealed that serum TNF-α level which 
plays important role in inflammatory symptoms 
induction and progression (2, 13, 24) decreased due to 
effective dose administration of calcium and it was 
along with the paw volume and hyperalgesia 
variations. One previous study showed that calcium 
pentosan polysulfate (CaPPS), a polysulfated 
polysaccharide, modulated TNF-α and IL-6 activity in 
fluids of the rat air-pouch model without affecting total 
pouch volume (14), but according to our previous 
studies reduction of serum levels of pro-inflammatory 
cytokines is one of the important targets for the 
treatment of inflammatory symptoms (2, 13). Studies 
suggested that CaPPS could represent a new class of 
disease-modifying anti-arthritic agents, but neither the 
anti-arthritic activity of the compound nor its effects on 
inflammatory mediators had been adequately 
investigated.  
Furthermore; transient changes in cytoplasmic 
calcium ion concentration represent a key step for 
neurotransmitter release and the modulation of cell 
membrane excitability. Evidence has accumulated for 
the involvement of calcium ions also in nociception 
and anti-nociception, including the analgesic effects 
produced by opioids (18). Our different studies also 
indicated during chronic inflammation spinal mu-
opioid receptor expression significantly increased (12). 
Intra-cerebra ventricular calcium administration 
caused naloxone-sensitive anti-nociception effects in 
mice (24). Although some other studies stated that the 
combination of opioids with drugs able to inhibit 
calcium ion functions in neurons has been pointed out 
as a useful alternative for safer clinical pain 
management (25) but others insist that calcium 
treatment via inhibition of voltage-gated Na+ channels 
can reduce the pain (24). 
 
Conclusion 
Then according to our study, it can be concluded that 
long-term administration of the effective dose of 
calcium can eliminate hyperalgesia and edema as 
inflammatory symptoms which it seems that, can be 
due to serum TNF-α level reduction during calcium 
treatment. The molecular and cellular aspects of these 
variations need more investigation. 
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